Shares of Mirum Pharmaceuticals, Inc. (MIRM) are soaring 8.72% in Thursday's trading session, following a wave of positive analyst revisions that have significantly boosted investor confidence in the biopharmaceutical company.

The stock's impressive rally comes on the heels of four major financial institutions raising their price targets for Mirum Pharmaceuticals. Citigroup led the charge with the most optimistic outlook, increasing its target price substantially from $72 to $89. H.C. Wainwright followed suit, lifting its target from $73 to $80, while Raymond James raised its projection from $77 to $82. Leerink Partners also joined the bullish sentiment, bumping its target from $56 to $66.

These widespread upgrades from respected financial institutions suggest growing confidence in Mirum Pharmaceuticals' future prospects. The company, which focuses on developing and commercializing novel therapies for debilitating liver diseases, appears to be gaining traction among analysts. As investors digest this influx of positive assessments, the stock's surge indicates that the market is reacting favorably to the improved outlook for MIRM. The significant uptick in share price underscores the impact of analyst opinions on investor sentiment and stock performance.